MorphoSys AG
XETRA:MOR
MorphoSys AG
Interest Income Expense
MorphoSys AG
Interest Income Expense Peer Comparison
Competitive Interest Income Expense Analysis
Latest Figures & CAGR of Competitors
Company | Interest Income Expense | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
MorphoSys AG
XETRA:MOR
|
Interest Income Expense
€42.5m
|
CAGR 3-Years
22%
|
CAGR 5-Years
134%
|
CAGR 10-Years
47%
|
|
BioNTech SE
NASDAQ:BNTX
|
Interest Income Expense
€313.5m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
121%
|
CAGR 10-Years
N/A
|
|
CureVac NV
NASDAQ:CVAC
|
Interest Income Expense
€14.2m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
53%
|
CAGR 10-Years
N/A
|
|
Immatics NV
NASDAQ:IMTX
|
Interest Income Expense
€4.7m
|
CAGR 3-Years
-24%
|
CAGR 5-Years
18%
|
CAGR 10-Years
N/A
|
|
Biotest AG
XETRA:BIO
|
Interest Income Expense
-€35.2m
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-42%
|
CAGR 10-Years
-19%
|
|
Formycon AG
XETRA:FYB
|
Interest Income Expense
€14.5m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is MorphoSys AG's Interest Income Expense?
Interest Income Expense
42.5m
EUR
Based on the financial report for Mar 31, 2024, MorphoSys AG's Interest Income Expense amounts to 42.5m EUR.
What is MorphoSys AG's Interest Income Expense growth rate?
Interest Income Expense CAGR 10Y
47%
The average annual Interest Income Expense growth rates for MorphoSys AG have been 22% over the past three years , 134% over the past five years , and 47% over the past ten years .